Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in therapy-resistant progressive immune-mediated interstitial pneumonitis
NL-OMON40302Phase 2Withdrawn
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in interstitial pneumonia, sponsored by St. Antonius Ziekenhuis. Primary endpoints: Pulmonary function improvement and Quality of life improvement. Planned start Apr 2014; status: withdrawn.
02
Drugs
rituximab
03
Conditions
interstitial pneumonia
Beyond the preview
Go deeper on NL-OMON40302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40302.